Our infographic details what to watch out for and when to consult your clinician
The grid below stacks naturally on smaller screens for clean reading on any device
Noticing symptoms like fatigue, headaches, or muscle cramps
Food and Drug Administration first approved semaglutide as Ozempic for type 2 diabetes in 2017 and as Wegovy for chronic weight management in 2021, and approved tirzepatide as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023
This compound, derived from angiotensin IV, has been shown to possess a wide range of biological activities, including enhancing cognitive function, promoting neurogenesis, and potentially mitigating the effects of neurodegenerative diseases
Osthole: A potential AMPK agonist that inhibits NLRP3 inflammasome activation by regulating mitochondrial homeostasis for combating rheumatoid arthritis